Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.

Original languageEnglish
Pages (from-to)413-417
Number of pages5
JournalRetina
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Choroidal Neovascularization
Intravitreal Injections
Visual Acuity
Fluorescein Angiography
Optical Coherence Tomography
Subretinal Fluid
Diabetic Retinopathy
Italy
Ranibizumab
Membranes

Keywords

  • Anti-VEGF drugs
  • Choroidal neovascularization
  • CNV
  • Microperimetry
  • Myopic CNV
  • Pathologic myopia
  • Ranibizumab
  • Retinal sensitivity
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. / Varano, Monica; Tedeschi, Massimiliano; Oddone, Francesco; Perillo, Loredana; Coppè, Andrea Maria; Parravano, Mariacristina.

In: Retina, Vol. 30, No. 3, 03.2010, p. 413-417.

Research output: Contribution to journalArticle

@article{120e9bf7761e4571bba5bd977905a01f,
title = "Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab",
abstract = "Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5{\%} to 72.7{\%}. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.",
keywords = "Anti-VEGF drugs, Choroidal neovascularization, CNV, Microperimetry, Myopic CNV, Pathologic myopia, Ranibizumab, Retinal sensitivity, Vascular endothelial growth factor",
author = "Monica Varano and Massimiliano Tedeschi and Francesco Oddone and Loredana Perillo and Copp{\`e}, {Andrea Maria} and Mariacristina Parravano",
year = "2010",
month = "3",
doi = "10.1097/IAE.0b013e3181bd2d23",
language = "English",
volume = "30",
pages = "413--417",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab

AU - Varano, Monica

AU - Tedeschi, Massimiliano

AU - Oddone, Francesco

AU - Perillo, Loredana

AU - Coppè, Andrea Maria

AU - Parravano, Mariacristina

PY - 2010/3

Y1 - 2010/3

N2 - Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.

AB - Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.

KW - Anti-VEGF drugs

KW - Choroidal neovascularization

KW - CNV

KW - Microperimetry

KW - Myopic CNV

KW - Pathologic myopia

KW - Ranibizumab

KW - Retinal sensitivity

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=77949381797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949381797&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181bd2d23

DO - 10.1097/IAE.0b013e3181bd2d23

M3 - Article

C2 - 20010453

AN - SCOPUS:77949381797

VL - 30

SP - 413

EP - 417

JO - Retina

JF - Retina

SN - 0275-004X

IS - 3

ER -